Kivara Neurosciences is advancing a multi-disciplinary molecular diagnostics platform that integrates metabolic biology, neurodegenerative biomarkers, epigenetics, cell-free DNA, and artificial intelligence to identify the earliest biological signals of disease before symptoms emerge.
Six scientific pillars converge into a single integrated diagnostic platform — designed to detect biological dysfunction years before clinical disease.
Research focused on beta-cell apoptosis as an early biological indicator of metabolic dysfunction and disease progression.
Integrating HbA1c, insulin, C-peptide, and additional metabolic signatures to better understand systemic metabolic health and disease risk.
Investigating epigenetic changes that may precede clinical disease and provide highly sensitive indicators of biological dysfunction.
Evaluating blood-based biomarkers associated with Alzheimer's disease, Multiple Sclerosis, and future neurodegenerative applications.
Leveraging circulating cell-free DNA to identify tissue-specific molecular signals through minimally invasive blood testing.
Developing machine learning algorithms that integrate multi-modal biomarker datasets into clinically actionable molecular intelligence.
Multiple scientific disciplines converge into one diagnostic pathway — a unified flow from sample to insight.
Where our scientific focus is concentrated today, and where the platform is expanding next.
Blood-based molecular biomarkers designed to identify disease before cognitive symptoms appear.
Developing novel biomarker strategies for earlier diagnosis and disease monitoring.
Investigating relationships between beta-cell biology, glucose regulation, insulin resistance, and neurodegenerative disease.
Building predictive algorithms capable of integrating diverse molecular datasets into precision diagnostics.
Intercept IQ™ is built as a scalable technology platform — not a single diagnostic.
The disciplined research and partnership strategy underpinning every Kivara program.
Partnerships with leading neuroscience and metabolic research centers.
Building well-characterized longitudinal sample repositories.
Rigorous analytical and clinical validation across cohorts.
Collaborations with clinical centers across neurology and metabolism.
Bridging discovery science with real-world diagnostic application.
Machine learning pipelines tuned to biological signal, not noise.
Future prospective studies designed for regulatory readiness.
A growing body of peer-reviewed research demonstrates that molecular changes associated with neurodegenerative disease may begin years — even decades — before clinical symptoms emerge. These findings, together with research linking metabolic dysfunction and impaired insulin signaling to Alzheimer's disease, provide an important scientific foundation for the development of next-generation blood-based molecular diagnostics.
This landmark study demonstrated that biological changes associated with Alzheimer's disease begin approximately 15–25 years before the onset of clinical symptoms. The findings transformed our understanding of Alzheimer's as a disease that develops silently over decades.
Introduced the widely accepted model describing the sequence of Alzheimer's biomarker changes over time, illustrating how amyloid accumulation, tau pathology, neurodegeneration, and cognitive decline occur progressively long before symptoms become clinically apparent.
This comprehensive review explores the biological relationship between insulin resistance, impaired glucose metabolism, and Alzheimer's disease, highlighting shared molecular pathways that support the growing connection between metabolic dysfunction and neurodegeneration.
One of the foundational publications demonstrating that insulin resistance and metabolic dysfunction play an important role in cognitive decline and Alzheimer's disease, helping establish the concept that metabolic health influences brain health.
This longitudinal study demonstrates that measurable biomarker changes can be detected over the two decades preceding a clinical diagnosis of Alzheimer's disease, reinforcing the importance of identifying disease biology before irreversible neurological damage occurs.
Kivara Neurosciences is developing next-generation molecular diagnostics informed by decades of peer-reviewed scientific research. Our goal is to advance blood-based molecular intelligence platforms capable of identifying disease-associated biological changes at the earliest possible stages, supporting future clinical research and precision medicine.
